Novartis Pharma Stein AG
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment of adult patients with chronic myeloid leukemia (Ph+ CML CP) in the chronic phase who have previously received two or more other tyrosine kinase inhibitors.
Dosage form: tablets, film-coated
Active substance Dosage asciminib 20 mg ATC: L01EA06
-
The drug is intended for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, if they have previously received two or more other tyrosine kinase inhibitors.
Dosage form: tablets, film-coated
Active substance Dosage asciminib 40 mg ATC: L01EA06
-
The drug is used as add-on therapy to achieve better control in the following conditions: severe persistent allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Dosage form: powder for injection solution
Active substance Dosage omalizumab 75 mg ATC: R03DX05
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Dosage form: powder for injection solution
Active substance Dosage omalizumab 150 mg ATC: R03DX05